The Board's Role in M&A


The M&A process can be seen as a litmus test for the health of the executive and non-executive team.

Criticaleye asks Liz Claydon, Simon Denham, Bob Emmins, Mark Garrett, Terry Stannard, Paul Staples, Anne Stevens and Jim Wilkinson why NEDs must challenge whether shareholder value is being created.

Share this with your Community


Contributors
Anne Stevens
Board Mentor
Criticaleye
Bob Emmins
Former Finance Director
The Silver Spoon Company
Jim Wilkinson
Chief Financial Officer
Oxford Sciences Innovation PLC
Liz Claydon
UK Head of Consumer Markets
KPMG, Canary Wharf, London
Mark Garrett
Strategic Advisor
Ceres Power Holdings
Paul Staples
Partner
Smith Square Partners
Simon Denham
Chief Risk Officer
TigerWit Group


Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.

Click here to download this insight
Driving Growth and Value as C...

Ithaca Energy has developed into a major player in the North Sea oil industry during Iain Lewis’ three years as CFO. In this interview with Criticaleye, he discusses the company’s IPO in 2022, its M&A st...

Click here to download this insight
Embracing the Human-AI Partne...

Singtel faces a rapidly changing environment as geopolitics, customer expectations and AI reshape its business. In discussion with Criticaleye Senior Editor Bridgette Hall, Group Chief People & Sustainability Office...

Click here to download this insight
Reaching New Heights at Guoco...

After four years in the Group CFO role at one of Singapore’s most prominent real estate developers, GuocoLand Group, Andrew Chew talks to Jacob Ambrose Willson about stepping up from regional CFO to Group, managin...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 436




NATS Drax Group plc FTSE Women Leaders Review Concentrix Google Salesforce Workday Aldermore Group Palo Alto Networks Legal & General Worldpay E.ON UK NatWest Group Eightfold AI IBM Consulting Lightsource bp London Stock Exchange Group Accenture AlixPartners Rolls-Royce British Land Hitachi Solutions GlaxoSmithKline plc